Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments.

McNamee P, Vanoli A, Hutchings D, McKeith I, Bond J.

J Nutr Health Aging. 2010 Oct;14(8):664-8.

PMID:
20922343
2.

Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Green C, Picot J, Loveman E, Takeda A, Kirby J, Clegg A.

Pharmacoeconomics. 2005;23(12):1271-82.

PMID:
16336020
3.

Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.

Getsios D, Blume S, Ishak KJ, Maclaine GD.

Pharmacoeconomics. 2010;28(5):411-27. doi: 10.2165/11531870-000000000-00000.

PMID:
20402542
4.
5.

Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.

Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G; AHEAD Study Group.

Clin Ther. 2003 Jun;25(6):1806-25.

PMID:
12860500
6.

Counting costs. Patients will suffer from limits on Alzheimer's drugs.

Page S.

Nurs Stand. 2005 May 25-31;19(37):24-5.

PMID:
15938410
7.

Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.

Marin D, Amaya K, Casciano R, Puder KL, Casciano J, Chang S, Snyder EH, Cheng I, Cuccia AJ.

Int Psychogeriatr. 2003 Dec;15(4):385-98.

PMID:
15000418
8.

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A.

Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. Review.

9.
10.

Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.

Versijpt J.

Acta Neurol Belg. 2012 Jun;112(2):141-5. doi: 10.1007/s13760-012-0062-9. Epub 2012 Apr 4. Review.

PMID:
22476975
11.

Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.

O'Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, Gauthier S.

J Am Geriatr Soc. 1999 May;47(5):570-8.

PMID:
10323651
13.

Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.

Lamb HM, Goa KL.

Pharmacoeconomics. 2001;19(3):303-18. Review.

PMID:
11303418
14.

NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?

Getsios D, Migliaccio-Walle K, Caro JJ.

Pharmacoeconomics. 2007;25(12):997-1006. Review.

PMID:
18047386
15.

The economic consequences of Alzheimer's disease in the context of new drug developments.

Knapp M, Wilkinson D, Wigglesworth R.

Int J Geriatr Psychiatry. 1998 Aug;13(8):531-43.

PMID:
9733334
16.

Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.

Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M, Davis S, Thokala P, Moxham T.

Age Ageing. 2013 Jan;42(1):14-20. doi: 10.1093/ageing/afs165. Epub 2012 Nov 22. Review.

17.
18.

Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.

Ward A, Caro JJ, Getsios D, Ishak K, O'Brien J, Bullock R; AHEAD Study Group.

Int J Geriatr Psychiatry. 2003 Aug;18(8):740-7.

PMID:
12891643
19.

Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Bosanquet N, Yeates A.

Pharmacoeconomics. 2006;24(6):623-5; author reply 625-6. No abstract available.

PMID:
16761908
20.

Assessing the societal impact of acetylcholinesterase inhibitor therapies.

Winblad B, Wimo A.

Alzheimer Dis Assoc Disord. 1999 Nov;13 Suppl 2:S9-19. Review.

PMID:
10622674
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk